Literature DB >> 10520638

Retinoic acid for treatment of multicentric Castleman's disease.

P Rieu, D Droz, A Gessain, J P Grünfeld, O Hermine.   

Abstract

Multicentric Castleman's syndrome has an aggressive course with poor prognosis, and its treatment remains uncertain. We report a woman with multicentric Castleman's disease that was successfully treated with prednisone and retinoic acid.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10520638     DOI： 10.1016/S0140-6736(99)03957-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  8 in total

1.  Multicentric Castleman's Disease.

Authors:  M K Gupta; S K Magu; A Behl
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy.

Authors:  Hee Yeon Seo; Eui Bae Kim; Jee Won Kim; Bong Kyoung Shin; Seok Jin Kim; Byung Soo Kim
Journal:  Cancer Res Treat       Date:  2009-06-30       Impact factor: 4.679

3.  Cases report of unicentric Castleman's disease: revisit of radiotherapy role.

Authors:  O Kyu Noh; Sang-Wook Lee; Jae Whan Lee; Sang Yoon Kim; Chung Soo Kim; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn
Journal:  Radiat Oncol J       Date:  2013-03-31

4.  Castleman's Disease with Cutaneous Involvement Manifestating as Multiple Violaceous Plaques on Entire Body.

Authors:  Hyeon-Young Park; Je-Jung Lee; Jee-Bum Lee; Seong-Jin Kim; Seung-Chul Lee; Young Ho Won; Sook Jung Yun
Journal:  Ann Dermatol       Date:  2011-10-31       Impact factor: 1.444

5.  β-HHVs and HHV-8 in Lymphoproliferative Disorders.

Authors:  C Quadrelli; P Barozzi; G Riva; D Vallerini; E Zanetti; L Potenza; F Forghieri; M Luppi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

6.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25

7.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

8.  Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.

Authors:  Zhen-gang Yuan; Xiao-yi Dun; Yong-hua Li; Jian Hou
Journal:  J Hematol Oncol       Date:  2009-04-28       Impact factor: 17.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.